524 related articles for article (PubMed ID: 19123458)
1. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
[TBL] [Abstract][Full Text] [Related]
2. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
3. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
4. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
5. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
Guglielmi C; Martelli M; Federico M; Zinzani PL; Vitolo U; Bellesi G; Santini G; Tarella C; Zallio F; Pregno P; Di Renzo N; Resegotti L;
Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622
[TBL] [Abstract][Full Text] [Related]
6. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
[TBL] [Abstract][Full Text] [Related]
7. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
Biol Blood Marrow Transplant; 2010 Mar; 16(3):376-83. PubMed ID: 19883776
[TBL] [Abstract][Full Text] [Related]
8. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
9. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
10. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
11. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio.
Porrata LF; Ristow K; Habermann T; Inwards DJ; Micallef IN; Markovic SN
Am J Hematol; 2010 Nov; 85(11):896-9. PubMed ID: 20842639
[TBL] [Abstract][Full Text] [Related]
12. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
[TBL] [Abstract][Full Text] [Related]
13. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
Bone Marrow Transplant; 2008 Apr; 41(8):715-20. PubMed ID: 18195687
[TBL] [Abstract][Full Text] [Related]
14. Absolute lymphocyte count predicts overall survival in follicular lymphomas.
Siddiqui M; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Call TG; Porrata LF
Br J Haematol; 2006 Sep; 134(6):596-601. PubMed ID: 16889618
[TBL] [Abstract][Full Text] [Related]
15. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.
Ege H; Gertz MA; Markovic SN; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Porrata LF
Br J Haematol; 2008 Jun; 141(6):792-8. PubMed ID: 18410454
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Song MK; Chung JS; Sung-Yong O; Lee GW; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ; Shin DH; Yun EY
Ann Hematol; 2010 Oct; 89(10):985-91. PubMed ID: 20428871
[TBL] [Abstract][Full Text] [Related]
17. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
[TBL] [Abstract][Full Text] [Related]
20. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
Jacobs NL; Holtan SG; Porrata LF; Markovic SN; Tefferi A; Steensma DP
Am J Hematol; 2010 Mar; 85(3):160-3. PubMed ID: 20131304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
